The Little ACO That Could

Cheryl ProvalThe press was full of stories earlier this month about the Pioneer ACOs that would exit the program. Are we surprised? If my employer told me I could play a game that, at the end of the year, would give me either a 10% bonus or a 10% penalty, I might be down with that—until I earned a penalty. What incentive would I have to put money at risk the next year? The only incentive I would have would be the lessons I learned in the process of trying to earn the bonus if—and this is a big if—I knew that the new game ultimately would become the only game. Fortunately, HHS offers an ACO environment with protection from the downside, the Shared Savings program, and many of the organizations exiting the Pioneer program have elected to put on the training wheels and opt for Shared Savings. Lesson learned: You can't flick a switch and become an ACO. While Crystal Run narrowly missed the opportunity to assume risk as a Pioneer ACO, it was named a Shared Savings ACO, and Gregory Spencer generously shares lessons that organization learned in its ACO journey in this month’s issue. One of those lessons—and a key predictor of ACO success—was to leverage data to support the initiatives of leadership, and Cleveland Clinic is blazing a trail to enterprise business intelligence, also described in this issue. Lastly, I recently had the opportunity to hear Blue Cross Blue Shield Association CFO Robert Kolodgy’s perspective on health care reform. It was part actuarial assessment and part plea for a new spirit of cooperation between providers and payors in transforming health care—as nothing less than that will work. I invite you to visit the HealthCXO portal at www.healthcxo.com launched just a few months ago, where you will find many stories of health care innovation. Go forth and innovate!Cheryl Proval
Cheryl Proval,

Vice President, Executive Editor, Radiology Business

Cheryl began her career in journalism when Wite-Out was a relatively new technology. During the past 16 years, she has covered radiology and followed developments in healthcare policy. She holds a BA in History from the University of Delaware and likes nothing better than a good story, well told.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.